Race Oncology Ltd (RAC)

Sydney
3.22
-0.04(-1.23%)
  • Volume:
    170,150
  • Bid/Ask:
    3.21/3.24
  • Day's Range:
    3.21 - 3.38

RAC Overview

Prev. Close
3.26
Day's Range
3.21 - 3.38
Revenue
20K
Open
3.3
52 wk Range
0.3 - 4.23
EPS
-0.04
Volume
170,150
Market Cap
418.15M
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
756,164
P/E Ratio
-
Beta
1.38
1-Year Change
776.32%
Shares Outstanding
129,458,875
Next Earnings Date
-
What is your sentiment on Race Oncology Ltd?
or
Vote to see community's results!

Race Oncology Ltd Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyBuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyBuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

Race Oncology Ltd Company Profile

Race Oncology Ltd Company Profile

Employees
0
Market
Australia

Race Oncology Limited, formerly Coronado Resources Limited, is an Australia-based specialty pharmaceutical company whose business model is to pursue and bring to market later stage assets, principally in the cancer field. The Company's Bisantrene drug is a chemotherapy drug, which is related to the anthracyclines, a class of drugs used as the first line of treatment for acute myeloid leukemia (AML) and other cancers. Its Bisantrene drug reduces cardiac toxicity compared to anthracyclines and to be effective against some cancers that have relapsed after the patients have already received high levels of anthracyclines, which makes Bisantrene as a second- or third-line treatment for patients reaching their cardio-toxic limit of anthracyclines or whose cancer has become resistant to anthracycline treatment. It has received orphan drug designation for Bisantrene in the United States. Its clinical opportunity for Bisantrene is used as a salvage treatment for elderly patients with AML.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.